Organon & Co. (OGN)
(Delayed Data from NYSE)
$19.49 USD
-0.69 (-3.42%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $19.50 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum B VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Revenue: Women?s Health Total
- 1,702.00
- 1,673.00
- 1,612.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Biosimilars Total
- 593.00
- 481.00
- 424.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands Total
- 3,847.00
- 3,874.00
- 4,068.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Other Total
- 121.00
- 146.00
- 200.00
- 58.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Women's Health: Nexplanon/Implanon NXT
- 830.00
- 834.00
- 769.00
- 165.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Women's Health: Follistim AQ
- 262.00
- 229.00
- 237.00
- 57.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Women's Health: NuvaRing
- 152.00
- 173.00
- 191.00
- 53.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Women's Health: Ganirelix Acetate Injection
- 110.00
- 123.00
- 111.00
- 25.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Biosimilars: Renflexis
- 278.00
- 226.00
- 186.00
- 39.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Biosimilars: Ontruzant
- 155.00
- 122.00
- 126.00
- 37.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Respiratory: Dulera
- 194.00
- 180.00
- 190.00
- 41.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Respiratory: Clarinex
- 136.00
- 125.00
- 111.00
- 21.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Respiratory: Other
- 77.00
- 83.00
- 89.00
- 9.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Non-Opioid Pain, Bone and Dermatology: Arcoxia
- 257.00
- 241.00
- 244.00
- 54.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Non-Opioid Pain, Bone and Dermatology: Fosamax
- 159.00
- 152.00
- 175.00
- 40.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Non-Opioid Pain, Bone and Dermatology: Diprospan
- 91.00
- 122.00
- 125.00
- 32.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Non-Opioid Pain, Bone and Dermatology: Other
- 275.00
- 273.00
- 50.00
- 50.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Other: Proscar
- 97.00
- 101.00
- 117.00
- 22.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Other: Propecia
- 125.00
- 125.00
- 136.00
- 39.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Other: Other
- 319.00
- 326.00
- 360.00
- 60.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Cardiovascular: Zetia
- 306.00
- 357.00
- 378.00
- 98.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Biosimilars: Hadlima
- 44.00
- 19.00
- 13.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Biosimilars: Aybintio
- 43.00
- 39.00
- 36.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Biosimilars: Brenzys
- 73.00
- 75.00
- 63.00
- 23.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Women's Health: Other
- 171.00
- 204.00
- 206.00
- 74.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Respiratory: Nasonex
- 253.00
- 238.00
- 206.00
- 57.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Cardiovascular: Vytorin
- 129.00
- 130.00
- 164.00
- 43.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Cardiovascular: Atozet
- 519.00
- 457.00
- 458.00
- 105.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Cardiovascular: Rosuzet
- 70.00
- 71.00
- 68.00
- 36.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Cardiovascular: Cozaar/Hyzaar
- 281.00
- 323.00
- 357.00
- 94.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Cardiovascular: Other
- 155.00
- 159.00
- 191.00
- 39.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Established Brands: Respiratory: Singulair
- 404.00
- 411.00
- 413.00
- 124.00
- --
- Revenue - Geographic (GEOR)
- Geographic Revenue: U.S.
- 1,478.00
- 1,437.00
- 1,383.00
- 1,408.00
- 2,021.00
- Revenue - Geographic (GEOR)
- Revenue: Women's Health: U.S.: Nexplanon/Implanon NXT
- 572.00
- 573.00
- 532.00
- 114.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Women's Health: Int'l: Nexplanon/Implanon NXT
- 257.00
- 261.00
- 237.00
- 50.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Women's Health: U.S.: Follistim AQ
- 136.00
- 105.00
- 110.00
- 24.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Women's Health: Int'l: Follistim AQ
- 136.00
- 124.00
- 127.00
- 33.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Women's Health: U.S.: NuvaRing
- 66.00
- 85.00
- 85.00
- 25.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Women's Health: Int'l: NuvaRing
- 86.00
- 88.00
- 106.00
- 28.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Women's Health: U.S.: Ganirelix Acetate Injection
- 19.00
- 26.00
- 22.00
- 4.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Women's Health: Int'l: Ganirelix Acetate Injection
- 91.00
- 97.00
- 88.00
- 21.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Women's Health: U.S.: Other
- 72.00
- 110.00
- 96.00
- 45.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Other: Proscar
- 96.00
- 99.00
- 116.00
- 22.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Other: Propecia
- 118.00
- 118.00
- 127.00
- 36.00
- --
- Revenue - Geographic (GEOR)
- Geographic Revenue: Other International
- 121.00
- 146.00
- 318.00
- 57.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Cardiovascular: Other
- 2.00
- 3.00
- 4.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Cardiovascular: Vytorin
- 6.00
- 8.00
- 11.00
- 3.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Biosimilars: U.S.: Renflexis
- 234.00
- 196.00
- 164.00
- 35.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Biosimilars: U.S.: Ontruzant
- 46.00
- 48.00
- 34.00
- 2.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Cardiovascular: Zetia
- 8.00
- 8.00
- 10.00
- 3.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Biosimilars: Int'l: Brenzys
- 73.00
- 75.00
- 63.00
- 23.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Biosimilars: Int'l: Aybintio
- 43.00
- 39.00
- 36.00
- 4.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Cardiovascular: Vytorin
- 124.00
- 123.00
- 153.00
- 40.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Cardiovascular: Atozet
- 519.00
- 457.00
- 458.00
- 105.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Cardiovascular: Rosuzet
- 70.00
- 71.00
- 68.00
- 36.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Cardiovascular: Cozaar/Hyzaar
- 272.00
- 310.00
- 345.00
- 90.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Respiratory: Singulair
- 393.00
- 400.00
- 398.00
- 120.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Respiratory: Nasonex
- 252.00
- 229.00
- 201.00
- 55.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Respiratory: Dulera
- 38.00
- 40.00
- 36.00
- 8.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Respiratory: Clarinex
- 132.00
- 121.00
- 106.00
- 19.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Non-Opioid Pain, Bone and Dermatology: Arcoxia
- 257.00
- 241.00
- 244.00
- 54.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Non-Opioid Pain, Bone and Dermatology: Fosamax
- 159.00
- 148.00
- 172.00
- 39.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Biosimilars: Int'l: Hadlima
- 26.00
- 19.00
- 13.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Non-Opioid Pain, Bone and Dermatology: Diprospan
- 91.00
- 122.00
- 125.00
- 32.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Non-Opioid Pain, Bone and Dermatology: Other
- 275.00
- 257.00
- 46.00
- 46.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Cardiovascular: Cozaar/Hyzaar
- 10.00
- 13.00
- 12.00
- 4.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Respiratory: Singulair
- 11.00
- 11.00
- 15.00
- 4.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Respiratory: Dulera
- 156.00
- 140.00
- 154.00
- 33.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Respiratory: Clarinex
- 5.00
- 4.00
- 6.00
- 2.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Non-Opioid Pain, Bone and Dermatology: Fosamax
- 3.00
- 4.00
- 4.00
- 1.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Non-Opioid Pain, Bone and Dermatology: Other
- 14.00
- 15.00
- 16.00
- 5.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Other: Propecia
- 7.00
- 7.00
- 9.00
- 2.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Other
- -1.00
- 24.00
- 41.00
- 9.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Other: Other
- 13.00
- 24.00
- -3.00
- 1.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Cardiovascular: Zetia
- 299.00
- 350.00
- 368.00
- 94.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Cardiovascular: Other
- 151.00
- 156.00
- 187.00
- 39.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Respiratory: Other
- 28.00
- 36.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: Int'l: Other: Other
- 308.00
- 302.00
- -3.00
- 50.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Established Brands: U.S.: Respiratory: Other
- 49.00
- 46.00
- 56.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Women's Health: Int'l: Other
- 101.00
- 94.00
- 111.00
- 30.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Biosimilars: Int'l: Renflexis
- 43.00
- 30.00
- 21.00
- 4.00
- --
- Revenue - Geographic (GEOR)
- Revenue: Biosimilars: Int'l: Ontruzant
- 109.00
- 74.00
- 92.00
- 35.00
- --